Literature DB >> 16699017

Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.

Hongyi Pan1, Jianping Xie, Fengchun Ye, Shou-Jiang Gao.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is etiologically associated with Kaposi's sarcoma, a dominant AIDS-related tumor of endothelial cells, and several other lymphoproliferative malignancies. While activation of the phosphatidylinositol 3-kinase-protein kinase C-MEK-ERK pathway is essential for KSHV infection, we have recently shown that KSHV also activates JNK and p38 mitogen-activated protein kinase (MAPK) pathways during primary infection (J. Xie, H. Y. Pan, S. Yoo, and S.-J. Gao, J. Virol. 79:15027-15037, 2005). Here, we found that activation of both JNK and p38 pathways was also essential for KSHV infection. Inhibitors of all three MAPK pathways reduced KSHV infectivity in both human umbilical vein endothelial cells (HUVEC) and 293 cells. These inhibitory effects were dose dependent and occurred at the virus entry stage of infection. Consistently, inhibition of all three MAPK pathways with dominant-negative constructs reduced KSHV infectivity whereas activation of the ERK pathway but not the JNK and p38 pathways enhanced KSHV infectivity. Importantly, inhibition of all three MAPK pathways also reduced the yield of infectious virions during KSHV productive infection of HUVEC. While the reduction of infectious virions was in part due to the reduced infectivity, it was also the result of direct modulation of KSHV lytic replication by the MAPK pathways. Accordingly, KSHV upregulated the expression of RTA (Orf50), a master transactivator of KSHV lytic replication, and activated its promoter during primary infection. Furthermore, KSHV activation of RTA promoter during primary infection was modulated by all three MAPK pathways, predominantly through their downstream target AP-1. Together, these results indicate that, by modulating multiple MAPK pathways, KSHV manipulates the host cells to facilitate its entry into the cells and postentry productive lytic replication during primary infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699017      PMCID: PMC1472170          DOI: 10.1128/JVI.02299-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  Integrin signaling.

Authors:  F G Giancotti; E Ruoslahti
Journal:  Science       Date:  1999-08-13       Impact factor: 47.728

2.  A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication.

Authors:  Yiyang Xu; David P AuCoin; Alicia Rodriguez Huete; Sylvia A Cei; Lisa J Hanson; Gregory S Pari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 3.  Intracellular pathogens and the actin cytoskeleton.

Authors:  S Dramsi; P Cossart
Journal:  Annu Rev Cell Dev Biol       Date:  1998       Impact factor: 13.827

4.  Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus.

Authors:  Jill T Bechtel; Richard C Winant; Don Ganem
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  RNAs in the virion of Kaposi's sarcoma-associated herpesvirus.

Authors:  Jill Bechtel; Adam Grundhoff; Don Ganem
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.

Authors:  Neelam Sharma-Walia; Harinivas H Krishnan; Pramod P Naranatt; Ling Zeng; Marilyn S Smith; Bala Chandran
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1).

Authors:  R Sarid; O Flore; R A Bohenzky; Y Chang; P S Moore
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 8.  Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.

Authors:  Lyubomir A Dourmishev; Assen L Dourmishev; Diana Palmeri; Robert A Schwartz; David M Lukac
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

9.  Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein.

Authors:  D M Lukac; R Renne; J R Kirshner; D Ganem
Journal:  Virology       Date:  1998-12-20       Impact factor: 3.616

10.  Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection.

Authors:  Khalief E Hamden; Patrick W Ford; Audy G Whitman; Ossie F Dyson; Shi-Yuan Cheng; James A McCubrey; Shaw M Akula
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  82 in total

1.  Gammaherpesvirus gene expression and DNA synthesis are facilitated by viral protein kinase and histone variant H2AX.

Authors:  Bryan C Mounce; Fei Chin Tsan; Lindsay Droit; Sarah Kohler; Justin M Reitsma; Lisa A Cirillo; Vera L Tarakanova
Journal:  Virology       Date:  2011-09-22       Impact factor: 3.616

2.  Cell membrane-bound Kaposi's sarcoma-associated herpesvirus-encoded glycoprotein B promotes virus latency by regulating expression of cellular Egr-1.

Authors:  Ossie F Dyson; Christopher M Traylen; Shaw M Akula
Journal:  J Biol Chem       Date:  2010-09-23       Impact factor: 5.157

3.  Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1.

Authors:  Arthur R Frampton; Donna B Stolz; Hiroaki Uchida; William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

Review 4.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

Review 5.  Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.

Authors:  Marie A Bogoyevitch; Bostjan Kobe
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

6.  Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA.

Authors:  Jiguo Chen; Fengchun Ye; Jianping Xie; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

7.  Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.

Authors:  Zhiqiang Qin; Lu Dai; Michael Defee; Victoria J Findlay; Dennis K Watson; Bryan P Toole; Jennifer Cameron; Francesca Peruzzi; Keith Kirkwood; Chris Parsons
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Authors:  Joshua C Johnson; Osvaldo Martinez; Anna N Honko; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  Antiviral Res       Date:  2014-05-09       Impact factor: 5.970

9.  Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway.

Authors:  Heidi J Zapata; Masako Nakatsugawa; Jennifer F Moffat
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin.

Authors:  Li-Wu Qian; Whitney Greene; Fengchun Ye; Shou-Jiang Gao
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.